Journal: Virology

Article Title: Oseltamivir inhibits influenza virus replication and transmission following ocular-only aerosol inoculation of ferrets

doi: 10.1016/j.virol.2015.06.020

Figure Lengend Snippet: Oseltamivir efficacy following OA inoculation of ferrets with HPAI H5N1 virus. Ferrets were inoculated by the OA route with Thai/16 virus at the doses reported in Table 1 and administered oseltamivir phosphate or distilled water as a control (n = 3 per group). (A), viral titers in nasal wash specimens were determined on the indicated days p.i. (B), tissues collected from control-treated ferrets euthanized due to neurological symptoms days 5–7 p.i. were titered for presence of infectious virus by standard plaque assay. NT, nasal turbinates; Tr, trachea; Lg, lung; BnOB, olfactory bulb; BnAnt, anterior brain; BnPos, posterior brain; Conj, conjunctiva; Lv, liver; Kd, kidney; Sp, spleen; Int, pooled intestine; Bd, blood. Bars represent individual ferrets. Limit of detection was 10 PFU/ml or g.

Article Snippet: Ferrets received control (distilled, sterile water) or 25 mg/kg of body weight/day oseltamivir phosphate (Sequoia Research Products, United Kingdom) suspended in 15% fructose orally twice daily (12.5 mg/kg per dose) from 2 h post-inoculation (p.i.) through day 5 p.i.

Techniques: Plaque Assay

Journal: Virology

Article Title: Oseltamivir inhibits influenza virus replication and transmission following ocular-only aerosol inoculation of ferrets

doi: 10.1016/j.virol.2015.06.020

Figure Lengend Snippet: Reduced influenza virus transmissibility in ferrets receiving oseltamivir following OA inoculation. Ferrets were inoculated by the OA route with Mex/7218 virus (A) or Mex/4482 virus (B) at the doses reported in Table 1 and administered oseltamivir phosphate (left column) or distilled water as a control (right column). A naïve ferret was placed in the same cage as each inoculated ferret at 24 h p.i. in order to assess virus transmission in the presence of direct contact. Nasal washes were collected from inoculated and contact ferrets on alternate days p.i. (solid bars) or p.c. (hatched bars). The limit of virus detection was 10 PFU/mL.

Article Snippet: Ferrets received control (distilled, sterile water) or 25 mg/kg of body weight/day oseltamivir phosphate (Sequoia Research Products, United Kingdom) suspended in 15% fructose orally twice daily (12.5 mg/kg per dose) from 2 h post-inoculation (p.i.) through day 5 p.i.

Techniques: Transmission Assay

Journal: Virology

Article Title: Oseltamivir inhibits influenza virus replication and transmission following ocular-only aerosol inoculation of ferrets

doi: 10.1016/j.virol.2015.06.020

Figure Lengend Snippet: Reduced H7N9 virus transmissibility in oseltamivir-treated ferrets receiving ocular-only or joint ocular-respiratory exposure. Oseltamivir-treated ferrets were inoculated by the OA route without (A) or with (B) respiratory (AR) exposure to Anhui/1 virus at the doses reported in Table 1, or inoculated by the OA route without respiratory exposure and administered distilled water as a control (C). A naïve ferret was placed in the same cage as each inoculated ferret at 24 h p.i. in order to assess virus transmission in the presence of direct contact. Nasal washes were collected from inoculated and contact ferrets on alternate days p.i. (solid bars) or p.c. (hatched bars). The limit of virus detection was 10 PFU/mL.

Article Snippet: Ferrets received control (distilled, sterile water) or 25 mg/kg of body weight/day oseltamivir phosphate (Sequoia Research Products, United Kingdom) suspended in 15% fructose orally twice daily (12.5 mg/kg per dose) from 2 h post-inoculation (p.i.) through day 5 p.i.

Techniques: Transmission Assay

Journal: Virology

Article Title: Oseltamivir inhibits influenza virus replication and transmission following ocular-only aerosol inoculation of ferrets

doi: 10.1016/j.virol.2015.06.020

Figure Lengend Snippet: Reduction of influenza virus yield by oseltamivir carboxylate in multiple cell types. MDCK (A), Calu-3 (B), or HCEpiC (C) cells were infected with H5N1, H7N9, H7N3, or H1N1 viruses at a MOI of 0.001 and cultured p.i. with medium containing the indicated quantity of oseltamivir carboxylate. 24 h (left column) or 48 h (right column) p.i., culture supernatant was sampled and titered for the presence of infectious virus by plaque assay. Values represent the mean+standard deviation for triplicate wells; limit of detection was 10 PFU/mL.

Article Snippet: Ferrets received control (distilled, sterile water) or 25 mg/kg of body weight/day oseltamivir phosphate (Sequoia Research Products, United Kingdom) suspended in 15% fructose orally twice daily (12.5 mg/kg per dose) from 2 h post-inoculation (p.i.) through day 5 p.i.

Techniques: Infection, Cell Culture, Plaque Assay, Standard Deviation

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: Inhibition of MDSC trafficking with SX-682, a CXCR1/2 inhibitor, enhances NK cell immunotherapy in head and neck cancer models

doi: 10.1158/1078-0432.CCR-19-2625

Figure Lengend Snippet: A, MOC2 tumor bearing mice were treated with SX-682 starting at day 7. At day 14, tumor single cell suspensions were assessed for live, CD45.2+CD11b+F4/80− myeloid cells by flow cytometry. Representative dot plots of gating strategy shown on the left, quantification (n=18) shown on the right. B, viability of CD45.2+ tumor leukocytes was determined by flow cytometry, quantification (n=18) shown. C, splenic PMN-MDSC or M-MDSC isolated from day mice bearing 14 day-old MOC2 tumors were fluorescently labelled and adoptively transferred (1×107 MDSC/mouse, n=5) into mice bearing 15 day-old MOC2 tumors treated with control or SX-682 chow beginning on day 7. Tumors were harvested and analyzed by flow cytometry 18 hours after adoptive transfer. Representative dot plots shown on the left, quantification of the number of fluorescently labelled MDSC that trafficked into tumors shown on the right. D, KIL were fluorescently labelled and adoptively transferred into day 10 MOC2 tumors in mice treated with or without SX-682 beginning at day 7. Four hours after injection of KIL, tumor single cell suspensions were assessed for KIL infiltration via fluorescent imaging (left panels) or flow cytometry. Representative dot plots are shown, with quantification (n=5) shown on the right. KIL were adoptively transferred into day 10 MOC2 tumors in mice treated with or without SX-682 beginning at day 7. E, CXCR1 and CXCR2 expression on KIL cells was assessed by flow cytometry, quantification shown. Twenty-four hours after injection, enriched leukocytes obtained via density gradient from MOC2 tumor single cell suspensions were assessed for IFNγ (F) or granzyme B (G) positivity following stimulation (PMA/Iono with brefeldin) by flow cytometry. Representative dot plots or histograms are shown on the left, with quantification (n=5) shown on the right. All representative data shown from one of at least two independent experiments with similar results. *, p<0.05; **, p<0.01; ***, p<0.001

Article Snippet: Control high fat chow and chow formulated with SX-682 (drug added to expose mice to 500 mg/kg body weight/day) was obtained from Research Diets, Inc. KIL were adoptively transferred via intraperitoneal injection.

Techniques: Flow Cytometry, Isolation, Adoptive Transfer Assay, Injection, Imaging, Expressing

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: Inhibition of MDSC trafficking with SX-682, a CXCR1/2 inhibitor, enhances NK cell immunotherapy in head and neck cancer models

doi: 10.1158/1078-0432.CCR-19-2625

Figure Lengend Snippet: A, Wild-type C57BL/6 mice harboring MOC2 tumors were treated with SX-682 (starting day 7, treatment for 7 days) alone or in combination with adoptively transferred KIL (starting day 7, 5×106 cells three times weekly for 2 weeks) and assessed for primary tumor growth (n=18–20 mice/group). Each line represents individual tumor growth. B, Day 20 tumor volumes for each treatment condition. C, Survival of treated MOC tumor-bearing mice, Kaplan-Meier survival curve shown. Cumulative data from three independent experiments shown. *, p<0.05; **, p<0.01; ***, p<0.001

Article Snippet: Control high fat chow and chow formulated with SX-682 (drug added to expose mice to 500 mg/kg body weight/day) was obtained from Research Diets, Inc. KIL were adoptively transferred via intraperitoneal injection.

Techniques: